Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma

NCT04990271 is registered in ClinicalTrials.gov with Chengdu Kanghong Biotech Co., Ltd. as lead sponsor.

NCT NCT04990271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04990271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma
Lead sponsor
Chengdu Kanghong Biotech Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
July 5, 2021
Completion date
July 15, 2023
Enrollment
92 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

retinoblastoma